Print

CEL-SCI (CVM) Receives Approval from Seven Hospital Institutional Review Boards in India to Commence Phase III Clinical Trial of Multikine in Head and Neck Cancer  
10/20/2010 10:54:11 AM

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE AMEX: CVM) announced today it has received approval from seven hospital Institutional Review Boards (“IRB”) in India to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare. CEL-SCI expects to have fifteen clinical centers in India, out of an expected forty-eight clinical centers world-wide. Head and neck cancer is the most prevalent form of cancer in India with about 200,000 new patients annually.
//-->